Diagnosis and management of osteoporosis

American Family Physician

Volumn 92, Issue 4, 2015, Pages 261-268

  Jeremiah, Michael P ^a   Unwin, Brian K ^a   Greenawald, Mark H ^a   Casiano, Vincent E ^b  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b EVANS ARMY COMMUNITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PIOGLITAZONE; RALOXIFENE; RISEDRONIC ACID; THYROTROPIN; BONE DENSITY CONSERVATION AGENT;

ALCOHOL CONSUMPTION; ARTICLE; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FALLING; FOLLOW UP; FRAGILITY FRACTURE; HORMONAL THERAPY; KIDNEY FAILURE; OSTEOPOROSIS; RISK FACTOR; SMOKING CESSATION; VITAMIN SUPPLEMENTATION; AGED; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 84940521964     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2014.
2. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, Md.: U.S. Department of Health and Human Services, Office of the Surgeon Gen­eral; 2004.
3. National Osteoporosis Foundation. America’s Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation; 2002.
4. World Health Organization. WHO scientific group on the assessment of osteoporosis at the primary health care level: summary meeting report. Brussels, Belgium; May 5-7, 2004. Geneva, Switzerland: World Health Organization; 2007.
5. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154(5):356-364.
6. Nayak S, Olkin I, Liu H, et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006;144(11):832-841.
7. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013; 16(4):455-466.
8. Gourlay ML, Fine JP, Preisser JS, et al.; Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteo­porosis in older women. N Engl J Med. 2012;366(3):225-233.
9. Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256-1262.
10. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77(5):453-468.
11. Cohen A, Fleischer J, Freeby MJ, McMahon DJ, Irani D, Shane E. Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health (Larchmt). 2009;18(1):79-84.
12. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008; 358(14):1474-1482.
13. Cerdá Gabaroi D, Peris P, Monegal A, et al. Search for hidden second­ary causes in postmenopausal women with osteoporosis. Menopause. 2010;17(1):135-139.
14. Management of osteoporosis in postmenopausal women: 2010 posi­tion statement of the North American Menopause Society. Menopause. 2010;17(1):25-54.
15. World Health Organization. Prevention and management of osteopo­rosis: report of a WHO Scientific Group. Geneva, Switzerland; 2003. http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf. Accessed September 6, 2014.
16. Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated system­atic review. Ann Intern Med. 2014;161(10):711-723.
17. Karinkanta S, Piirtola M, Sievänen H, Uusi-Rasi K, Kannus P. Physical therapy approaches to reduce fall and fracture risk among older adults. Nat Rev Endocrinol. 2010;6(7):396-407.
18. Moyer VA; U.S. Preventive Services Task Force. Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(3):197-204.
19. Giangregorio LM, Papaioannou A, Macintyre NJ, et al. Too fit to frac­ture: exercise recommendations for individuals with osteoporosis or osteoporotic vertebral fracture. Osteoporos Int. 2014;25(3):821-835.
20. American Geriatrics Society. AGS/BGS Clinical Practice Guideline for the Prevention of Falls in Older Persons. New York, NY: American Geriatrics Society; 2010.
21. Santesso N, Carrasco-Labra A, Brignardello-Peterson R. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev. 2014;(3):CD001255.
22. Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int. 2012;23(8):2081-2092.
23. Maurel DB, Boisseau N, Benhamou CL, Jaffre C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int. 2012;23(1):1-16.
24. Body JJ, Bergmann P, Boonen S, et al. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int. 2011;22(11):2769-2788.
25. Sambrook PN, Cameron ID, Chen JS, et al. Does increased sunlight expo­sure work as a strategy to improve vitamin D status in the elderly: a clus­ter randomised controlled trial. Osteoporos Int. 2012;23(2):615-624.
26. MacLean C, Newberry S, Maglione M, et al. Systematic review: com­parative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148(3):197-213.
27. Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther. 2014;56(1452):91-96.
28. First Databank, Inc. AnalySource Monthly. http://www.fdbhealth.com/policies/drug-pricing-policy. Accessed September 5, 2014.
29. Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treat­ment of osteoporosis. Am Fam Physician. 2009;79(3):193-200.
30. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006;26(5):427-431.
31. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-610.
32. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glu­cocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202-211.
33. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277-285.
34. Chesnut CH III, Skag A, Christiansen C, et al.; Oral Ibandronate Osteo­porosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249.
35. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022.
36. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18): 1714-1723.
37. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injec­tions in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838-1846.
38. Black DM, Schwartz AV, Ensrud KE, et al.; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
39. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145(3):235]. Ann Intern Med. 2006; 144(10):753-761.
40. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occur­rence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172(12):930-936.
41. Silverman SL, Azria M. The analgesic role of calcitonin following osteo­porotic fracture. Osteoporos Int. 2002;13(11):858-867.
42. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associ­ated cancer risk. Ann Pharmacother. 2013;47(12):1675-1684.
43. Black DM, Bilezikian JP, Ensrud KE, et al.; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-565.
44. Cummings SR, San Martin J, McClung MR, et al.; FREEDOM Trial. Deno­sumab for prevention of fractures in postmenopausal women with osteoporosis. published correction appears in N Engl J Med. 2009; 361(19):1914.N Engl J Med. 2009;361(8):756-765.
45. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829-1835.
46. Cauley JA, Robbins J, Chen Z, et al.; Women’s Health Initiative Investi­gators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.
47. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxypro­gesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668-2676.
48. Lewiecki EM. Bone density monitoring to monitor osteoporosis therapy in clinical practice. Am Fam Physician. 2010;82(7):749-754.
49. Combs BP, Rappaport M, Caverly TJ, Matlock DD. “Due” for a scan: examining the utility of monitoring densitometry. JAMA Intern Med. 2013;173(21):2007-2009.